Under-eye filler FDA approval: verify the exact infraorbital product and plane
Several hyaluronic-acid fillers have product-specific FDA approvals for defined infraorbital volume deficits in adults. Approval applies to the named formulation, age, anatomy, plane, labeling, and technique—not every filler, tear trough, eyelid, orbital area, injection plane, or patient.
FDA approval for under-eye filler is product-specific. The May 2026 RHA Redensity Eye and RHA Redensity Eye Lido supplement covers correction of moderate-to-severe tissue-volume deficiency in the infraorbital region of adults 22 and older using the labeled subdermal and supraperiosteal planes. It does not approve every filler, every periorbital placement, every hollow or bag, or an injector’s preferred off-label technique.123
Other named products also have their own under-eye approvals, including Restylane Eyelight.4 “Under-eye filler is approved” is therefore both true in a limited sense and too vague to support a booking. The record must identify product, formulation, indication, age, anatomy, plane, instructions, and the concern being treated.
Approval belongs to the finished product, not the syringe category
Hyaluronic-acid fillers are not interchangeable generics. Products vary in formulation, concentration, crosslinking, rheology, syringe, needle, anesthetic, labeling, studied technique, and evidence.
| Claim | Record needed | What not to infer |
|---|---|---|
| FDA approved for under eyes | Exact PMA supplement and current labeling | That the whole brand family or any HA filler is approved |
| Approved for tear troughs | Label's defined infraorbital indication and anatomical illustrations | That every eyelid, malar bag, edema or dark-circle cause is included |
| Approved technique | Named injection plane, instrument and instructions | That any depth, bolus, cannula pattern or combination is on-label |
| Clinically proven result | Pivotal endpoint, timepoint and studied population | That an individual will have the average response or duration |
RHA Redensity Eye contains mepivacaine; Eye Lido contains lidocaine. The shared indication does not make their anesthetic ingredients irrelevant. Allergy and exposure review must name the exact presentation.
“Under-eye hollow” is not a diagnosis
Shadowing can come from skeletal contour, ligament transition, fat compartments, cheek volume, skin quality, pigmentation, vessels, edema, festoons, eyelid position, lighting, or combinations. Filler adds material; it does not remove pigment, tighten every lax eyelid, treat fluid tendency, or reposition prolapsed fat in the same way as surgery.
A structured assessment should document:
- the finding at rest and with expression in neutral lighting;
- lower-lid support and prior eyelid or facial surgery;
- edema, morning fluctuation, allergy or sinus history;
- bags, festoons, skin laxity, pigment and vascular show;
- cheek and skeletal support;
- existing filler, product, date, plane, and imaging if available;
- what the proposed product is expected to change and what will remain.
The under-eye filler, PRF and surgery comparison owns the route decision. This page answers the narrower regulatory question after filler is being considered.
Read plane and anatomy together
The 2026 approval materials name subdermal and supraperiosteal injection planes for the defined product and indication.3 That does not mean the entire infraorbital region is one uniform safe layer. Vessels, nerves, orbital structures, retaining ligaments, prior filler, scars, and thin skin change the plan.
Ask the injector to mark the intended region and state:
- product and presentation;
- plane by subregion;
- needle or cannula, entry points, and rationale;
- planned amount by side and stopping rule;
- whether ultrasound is used and what decision it would change;
- emergency supplies, transfer plan, and after-hours contact.
FDA approval does not eliminate the rare but serious risk of inadvertent intravascular injection, including tissue injury, visual impairment, blindness, or stroke described in filler labeling. The vascular-occlusion plan explains why recognition, hyaluronidase access for HA product, escalation, and time matter.
Build a product-specific approval inventory
RHA Redensity Eye and Eye Lido are not the first or only fillers with a U.S. under-eye indication. FDA has product-specific records for Restylane Eyelight, Belotero Balance, and Juvéderm Volbella XC, among others. Their approved wording, age, depth, instrument, amount, study design and labeling are not necessarily identical.4
When a practice advertises “the only FDA-approved tear-trough filler” or “all FDA-approved eye fillers,” note the date of the statement and search the live PMA database. Product status can change, and a family name may include several formulations with only one approved for the area. Ask whether the syringe shown in consent is the same one named in the approval record.
This is also why generic FDA web summaries can lag recent PMA supplements. Use the product’s current decision and labeling as the controlling record for its indication. A newer approval does not retroactively make past uses on-label.
Edema and contour behavior deserve their own plan
The infraorbital region can reveal small differences in material, plane and water attraction. Discuss prior or morning-predominant swelling, malar edema, festoons, allergy patterns, lymphatic or surgical history, and existing filler before adding product. A volume deficit and an edema-prone contour can coexist; correcting one may not improve the other.
The follow-up should distinguish expected early swelling from persistent edema, palpable or visible product, color change, asymmetry, inflammation, infection and vascular symptoms. “Wait two weeks” should not be the only instruction when urgent features are possible.
For hyaluronic-acid filler, hyaluronidase may be considered in selected situations, but dissolving is not a reset button. Response can be uneven, multiple sessions may be discussed, and reversal does not treat every cause of under-eye shadow or swelling. Request a written correction ladder and who pays for evaluation, imaging, dissolving or specialist care.
Evidence supports the studied endpoint, not every marketing claim
Read the Summary of Safety and Effectiveness Data for eligibility, baseline severity, evaluator scales, follow-up, retreatment rules, adverse events, exclusions, sponsor, and missing data.3 The primary endpoint concerns correction of a defined volume deficit. It does not prove treatment of dark circles from pigment, eye bags, festoons, dry eye, or global facial rejuvenation.
Duration in a group does not promise duration for one person. Product amount, metabolism, tissue movement, prior filler, anatomy, technique, endpoint, and retreatment threshold differ. “Lasts a year” should be translated into the study timepoint and the proportion meeting a defined response, not a calendar guarantee.
A product inventory prevents silent substitution
At consultation and treatment, preserve:
If the product changes because of inventory, price, or injector preference, the consent and regulatory comparison should restart. A signed consent for “HA filler” does not document product-specific approval.
Approval is not injector certification
FDA evaluates devices and their labeling; it does not license injectors or certify a clinic’s technique. Verify the individual’s current professional license, the authority and supervision applicable to the service, training relevant to the infraorbital region, and complication readiness. Treomark’s Florida injector guide separates product status from professional authority.
Compare quotes by exact product, syringe allocation, amount likely used versus opened, imaging, follow-up, included correction, emergency care, and management of persistent edema or an unsatisfactory contour. Do not compare only “one syringe.”
The decisive question
Ask: “Which exact product and PMA supplement cover this exact infraorbital finding, age and plane—and which parts of your plan are outside that labeling?” A responsible injector can answer without pretending that off-label automatically means wrong or that approval makes the under-eye simple.
Sources
- U.S. Food and Drug Administration. PMA supplement P170002/S050—RHA Redensity Eye and Eye Lido. May 2026 product-specific approval for moderate-to-severe infraorbital tissue-volume deficiency in adults 22 and older, with labeling links. Accessed .
- U.S. Food and Drug Administration. RHA Redensity Eye and Eye Lido approval order. Official approval action and conditions. Accessed .
- U.S. Food and Drug Administration. RHA Redensity Eye and Eye Lido safety and effectiveness summary. Study design, population, injection planes, endpoints, adverse events, and evidence limits. Accessed .
- U.S. Food and Drug Administration. Restylane Eyelight—recently approved device. Another product-specific under-eye approval record illustrating why the exact filler must be named. Accessed .